Cytomegalovirus (CMV) Infection Market
As per the Delveinsight, the total number of diagnosed cytomegalovirus patients in the 7MM were found to be 110,580 in 2017.
The cytomegalovirus infection market in the 7MM was estimated to be approx. USD 1195.27 million in 2017. The United States was observed to hold the highest market share of the Cytomegalovirus infection market among 7MM.
The key companies in the Cytomegalovirus (CMV) Infection Market includes BioTest, Merck Sharp & Dohme Corp, Shire, Atara Biotherapeutics, ViraCyte and many others.
For more detailed information on Cytomegalovirus (CMV) Infection Market, visit: https://www.delveinsight.com/blog/cytomegalovirus-seroprevalence-market/
Polycythemia Vera Market
The total prevalent population of Polycythemia Vera in the 7MM was 283,442 in 2017. The estimates show the highest prevalence of Polycythemia Vera in the United States with 157,290 cases in 2017. It is also observed that Males are more affected by Polycythemia Vera as compared to females in the 7MM market.
The therapeutic market of Polycythemia Vera in the seven major markets was assessed to be USD 951.68 Million in 2017 and is expected to grow during the study period (2017–2030).
For more detailed information on Polycythemia Vera market, visit:
https://www.delveinsight.com/report-store/polycythemia-vera-market
Vernal keratoconjunctivitis Market
Vernal Keratoconjunctivitis may represent as 3% of serious ophthalmic disease. In addition, the prevalence is about 1 in 5000 cases of eye disease in Northern Europe and North America.
A Japanese epidemiologic study (Uchio EKimura et al, 2008) showed that VKC accounted for 4% of all ocular allergies with a low mean age of patients and severe clinical presentation.
According to the World Allergy Organization, males are more frequently affected than females, with a ratio of 3:1. The disease usually begins before the age of 10 years and remits at the time of puberty, although the age of affected individuals ranges from 3 to 25 years of age.
For more information on Vernal keratoconjunctivitis Market, visit:
https://www.delveinsight.com/report-store/vernal-keratoconjunctivitis-market
Essential Thrombocythemia Market
Essential Thrombocythemia (ET), an uncommon blood cancer, is one of the classic myeloproliferative neoplasms. It is a condition in which the bone marrow produces too many platelets. Patients with ET have increased numbers of platelets. Red blood cell numbers are generally normal in ET, while white blood cell numbers are normal or slightly elevated in ET.
The estimates show the highest prevalence of ET in the United States with 142,635 cases.
The total prevalent population of Essential Thrombocythemia in the 7MM was 232,688 in 2017.
Among the European five countries, France had the highest prevalent population of Essential Thrombocythemia with 20,141 cases, followed by Germany and the United Kingdom.
A higher percentage of symptomatic prevalence was observed in the US, in comparison to other 7MM countries during the study period (2017–2030).
For more information on Essential Thrombocythemia Market, visit:
https://www.delveinsight.com/report-store/essential-thrombocythemia-ET-market-insights
Cancer Cachexia Market
Cancer cachexia is a wasting syndrome, which is characterized by weight loss, anorexia (loss of desire to eat), asthenia and anemia. The pathogenicity of this syndrome is multifactorial, due to a complex interaction of tumor and host factors.
According to the Cancer Cachexia Hub, approximately half of all patients with cancer experience cachexia. This rate of occurrence rises to as high as 86% in the last 1–2 weeks of life, and with 45% of patients losing more than 10% of their original body weight over disease progression.
cachexia occurs in the majority of terminal cancer patients and is responsible for the death of 22% of cancer patients [As per a Japanese study conducted by Aoyagi et al.].
Among late stage patients, cachexia affects 50–80% of cancer patients
According to a study conducted by Advani et al., “cancer cachexia impacts approximately 60% of the 1.4 million patients diagnosed with cancer in the United States each year.
For more detailed information on Cancer Cachexia Market visit: https://www.delveinsight.com/report-store/Cancer-cachexia-CC-market-insights
Aneurysmal Subarachnoid Hemorrhage Market
A subarachnoid hemorrhage (SAH) is bleeding in the space between the brain and the surrounding membrane (subarachnoid space), causing a sudden and severe headache.
Bleeding that results from the rupture of an abnormal bulge in a blood vessel (aneurysm) in the brain is known as Aneurysmal Subarachnoid Hemorrhage (aSAH).
Aneurysmal Subarachnoid Hemorrhage Market Key Facts
The incident cases of aSAH is more common in females as compared to males.
The majority of SAH patients develop angiographic vasoconstriction (up to 70%), and only around 20–30% develop DCI [As per the study conducted by Francoeur et al.].
The study conducted by Tamimi et al.”estimated the incidence of aneurysmal subarachnoid hemorrhage (aSAH) to be 6–8 per 100,000 annually, with a peak incidence in the fifth decade”.
For more detailed information on Aneurysmal Subarachnoid Hemorrhage Market visit:
https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
Acute Lymphocytic Leukemia Market
The total incident cases of Acute Lymphocytic Leukemia in the 7MM were 10,341 in 2017. ALL is more frequent in males as compared to females.
The market size of Acute Lymphocytic Leukemia in the 7MM was found to be USD 1,246 Million in 2017.
Increasing focus towards the development of targeted therapies, rising occurrence of ALL, improvement in the diagnosis and awareness, and competitive landscape are some of the key factors expected to drive the ALL market in the coming years.
The key players in the Acute Lymphocytic Leukemia market includes Pharmacyclics, Takara Bio/ Otsuka, Jazz Pharmaceutical, Bellicum Pharmaceuticals, Precision BioSciences, Allogene Therapeutics, Novartis, Autolus, Janssen Pharmaceuticals, Gamida Cell, BioLineRx, Bristol-Myers Squibb, Pfizer, Fate Therapeutics, Gilead Sciences, Sanofi, TCR2 Therapeutics, Miltenyi Biotec, AbbVie and others.
For more detailed information on Acute Lymphocytic Leukemia Market, visit: https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market
Can medical marijuana help people with Alzheimer?
Alzheimer’s is one of the most common causes of dementia. Alzheimer’s accounts for nearly two-third cases of dementia. As per Centers for Disease Control and Prevention (CDC), in 2014, “an estimated 5 million Americans aged 65 years or older had Alzheimer’s disease. This number is projected to nearly triple to 14 million people by 2060”. Also a very high cost of treatment is projected to be incurred over the coming years.
As of now only a limited study has been conducted to find the effect of medical marijuana on the Alzheimer’s patients. The studies conducted have not been able to find hard evidence that marijuana or its compound can prevent or stop the Alzheimer’ disease. But few studies have suggested that medical marijuana can be productive for treating neuropsychiatric symptoms (or behavioral symptoms) linked to dementia such as agitation, mood, aggression, nocturnal behavior disorders, irritability, disinhibition, aberrant vocalization and so on.
A more comprehensive study is required in this field to assess the long term effects of cannabis on brain keeping the side-effects and person’s safety in mind.
For more details visit: https://www.delveinsight.com/blog/medical-marijuana-and-alzheimer-disease/
Interstitial Cystitis Market
The total diagnosed prevalent population of Interstitial Cystitis in the 7MM was 2,264,118 in 2017. The diagnosed prevalent cases of Interstitial Cystitis in the United States were found to be 1,459,502 in 2017. It is observed that womens are more affected with IC as compared to males.
The market size of Interstitial Cystitis in the 7MM was USD 1,599 Million in 2017, which is expected to increase during the forecast period 2017-2030.
FDA approved oral medication, increasing emerging therapies, increasing awareness are some of the key factors expected to drive the IC market in the coming years.
The key companies in the therapeutics market of Interstitial Cystitis includes KYORIN Pharmaceutical, UCB, Grünenthal, Astellas Pharma, Lipella Pharmaceuticals, SEIKAGAKU CORPORATION and many others.
For more information visit: https://www.delveinsight.com/report-store/interstitial-cystitis-market
Prosthetic Joint Infection Market
The total incident cases of Prosthetic Joint Infection in 7MM and China was 66,811 in 2017. It has been observed that Males are more affected with PJI as compared to females.
The market size of Prosthetic Joint Infection in the seven major markets and China was found to be USD 61.63 Million in 2017.
Increasing number of joint arthroplasties, rapid technology development in china, favourable environment for anti-infective modalities, advancement in human genomics are some of the key factors expected to drive the Prosthetic Joint Infection market in the upcoming years.
The key players in the Prosthetic Joint Infection market include Arrevus, TenNor Therapeutics, ContraFect Corporation, Peptilogics, Joint Purification Systems, and others.
For more detailed information on Prosthetic Joint Infection Market, visit: https://www.delveinsight.com/report-store/prosthetic-joint-infection-market
Geographic Atrophy Market
According to a study by Brader et al. (n.d.), an estimated number of 7–10 million Americans show early signs of developing age-related macular degeneration and are at significant risk of progression of AMD to advanced levels and Geographic Atrophy. In over a 15 year-time period, incidence of progression from early AMD to GA is estimated to be 14%.
The key companies in the Geographic Atrophy Market includes Apellis Pharmaceuticals, Alkeus Pharmaceuticals, Regenerative Patch Technologies, Ionis Pharmaceuticals, IVERIC bio (Opthotech), Alimera Sciences, Genentech, Gyroscope Therapeutics and others
For more details visit: https://www.delveinsight.com/blog/geographic-atrophy-market-size/
Diabetic Peripheral Neuropathy Market Analysis
As per DelveInsight, total Diabetic Peripheral Neuropathy diagnosed prevalent cases are expected to reach 25,860,249 in the 7MM by 2020 from 25,332,829 in 2017. The United States is expected to account for the maximum total Painful Diabetic Peripheral Neuropathy Prevalent Cases. Moreover, a higher female disposition is observed in DPN.
The Diabetic Peripheral Neuropathy Market is expected to grow with a CAGR of 12% by 2030 attributed to increasing DPN prevalence, and introduction to gene therapies in the pipeline.
The key players in the Diabetic Peripheral Neuropathy market includes Helixmith, Aptinyx Inc., WinSanTor, Regenacy Pharmaceuticals LLC, Novaremed AG, Glenmark Pharmaceuticals, Grünenthal Group, and others.
For more details visit: https://www.delveinsight.com/blog/diabetic-peripheral-neuropathy-market-landscape/
High-Grade Glioma Market
High-Grade Glioma are tumors of the central nervous system (CNS). They are solid tumors arising from transformed cells called astrocytes of the brain and/or the spinal cord.
The incidence rate of High-Grade Glioma is 5-10 new diagnoses per 1,000,000 children per year. HGGs accounts for nearly 15-20% of CNS tumours in children and adolescents. It has been observed that HGG is more common in men than in women.
The key players in the High-Grade Glioma Market includes BioMimetix, Oncoceutics, Inc., Bristol-Myers Squibb, Istari Oncology, Aadi Bioscience, Sumitomo Dainippon Pharma, Novartis, Kazia Therapeutics, and others.
For more details visit: https://www.delveinsight.com/report-store/high-grade-glioma-market
Familial Hypercholesterolemia Market
The total diagnosed prevalent population of Familial Hypercholesterolemia (FH) in the 7MM was 965,405 in 2017, which is anticipated to increase by 2030. Also, the diagnosed prevalent population of FH was found to be 244,214 in the United States during the same period.
The market size of Familial Hypercholesterolemia in the 7MM was found to be USD 1,069.27 Million in 2017.
Emerging therapies and promising organizations are some of the key factors expected to drive the FH market in the coming years, while late diagnosis, differential diagnosis, lack of Homozygous FH (HoFH) are major barriers in the advancement of the Familial Hypercholesterolemia market.
The key players in the Familial Hypercholesterolemia market includes Regeneron Pharmaceuticals, Novartis, Arrowhead Pharmaceuticals, NeuroBo Pharmaceuticals, Madrigal Pharmaceuticals, and others.
For more information visit: https://www.delveinsight.com/report-store/familial-hypercholesterolemia-type-ii-hyperlipoproteinemia-market
Causes and Risk Factors of Alzheimer's
As per World Health Organization, “50 million people globally have dementia, and out of all the dementia cases, Alzheimer's Disease accounts for about 60–70% of cases”.
Alzheimer’s is a neurodegenerative disease, a common cause of dementia that affects behavior, memory, and thinking abilities of an individual. Mostly the symptoms appear in the 60’s but in rare cases early onset during the late 40’s has also been observed.
The cause of Alzheimer’s varies from person to person. Largely Alzheimer’s is of sporadic origin. The genetics, lifestyle and environmental factors are considered to be important factors contributing to the development of AD. However, the exact cause of the disease still remains in the dark.
Apart from these some other factors such as Vascular Diseases, Depression, Brain Injury, Type 2 diabetes, epilepsy, poor diet, social isolation also induce the risk of Alzheimer’s.
For more details visit
https://www.delveinsight.com/blog/alzheimers-disease-risk-factors/
Postpartum Depression Market
In the 7MM, the total diagnosed prevalent cases of Postpartum Depression in 2017 were 1,134,800. With 609,900 cases, the United States accounts for the highest diagnosed prevalent population of Postpartum Depression.
The market size of Postpartum Depression in 7MM was found to be USD 138.75 Million in 2017.
The key players in the Postpartum Depression market include Sage Therapeutics, Marinus Pharmaceuticals, and others.
For more details visit: https://www.delveinsight.com/report-store/postpartum-depression-market
Diabetic Peripheral Neuropathy Market
According to DelveInsight, the total diagnosed prevalent population of Diabetic Peripheral Neuropathy in 7 Major Markets was 25,332,829 in 2017.
Diabetic Peripheral Neuropathy Market is anticipated to grow with a CAGR of 12% for the study period of 2017-2030.
The key players in Diabetic Peripheral Neuropathy market includes Helixmith, Aptinyx Inc., WinSanTor, Regenacy Pharmaceuticals LLC, Novaremed AG., Grünenthal Group, Glenmark Pharmaceuticals and others.
Diabetic Peripheral Neuropathy Market is expected to increase due to the increasing global burden of diabetes, advancement in early diagnosis and the launch of the promising therapies in the upcoming years.
For more details, visit:
https://www.delveinsight.com/blog/diabetic-peripheral-neuropathy-market/
Burns are injuries primarily to the skin and the underlying tissue. The skin is the largest organ in the body and it regulates the body’s temperature. It also prevents the evaporation of body fluids and acts as a barrier against infection.
Skin Burns Market Key Facts
-The total incident population of Skin Burns in the 7 MM was estimated to be approximately 2,881,995 cases out of which 15,49,983 were hospital visit cases in 2017.
-Among the European countries, Germany had the maximum incident cases followed by France.
-Spain had the lowest number of incident cases in 2017 among seven major markets.
-Thermal burns from dry sources (fire or flame) and wet sources (scalds) account for approximately 80 % of all reported burns [ Matthew P. Rowan et. al. 2015].
-Total Severity Specific incident cases in the United States were found to be 602,957 in 2017.
For more details visit: https://www.delveinsight.com/report-store/skin-burns-market
The Herpes Simplex Virus, also known as HSV, is an infection which leads to small, painful, fluid-filled blisters on the skin, mouth, lips, eyes or genitals. This infection is categorized into two types:
Herpes Simplex Virus Type-1 (HSV-1) & Herpes Simplex Virus Type-2 (HSV-2)
-As per WHO’s estimate in 2017, there were about 3.7 billion people under the age 50 (67%) with HSV-1 infection globally and an estimated 417 million people aged 15-49 (11%) worldwide were affected with HSV-2 infection.
-As per the Centers for Disease Control and Prevention, approximately, 776,000 people in the United States develop new Herpes Infections, while one out of every six people aged 14 to 49 years have Genital.
-As per American Academy of Pediatrics, Most people are first exposed to HSV between 1 and 5 years of age.
For more details visit: https://www.delveinsight.com/report-store/herpes-simplex-market
Hepatitis B Virus Infection Market
Hepatitis B is potentially a life-threatening liver infection caused by the Hepatitis B Virus (HBV). It is a major global health problem and it can be an acute infection or a chronic infection. Chronic HBV infection is a leading cause of chronic hepatitis and advanced-stage liver diseases, including cirrhosis and hepatocellular carcinoma (HCC).
-HBV Infection is estimated to have 786,000 deaths and the vast majority being attributable to liver cancer (341,000 deaths) and cirrhosis (312,000 deaths), as per [Lozano et al., 2012].
-According to the WHO, about 2 billion people worldwide have been infected with the Hepatitis B Virus and about 360 million live with chronic Hepatitis B infection.
-The global prevalence of HBV infection varies widely.
-HBV infection ranks 15th among all causes of human mortality [Lozano et al., 2012]
-The global prevalence of HBV infection varies widely. It ranges from <0.5 % in areas of low endemicity (e.g., North America and some Western European countries) to rates above 8% in the highly endemic countries of Sub-Saharan Africa and East Asia.
For more details, visit:
https://www.delveinsight.com/report-store/hepatitis-b-virus-hbv-infection-market
Joined Feb 2020
